Trial of Enteral Glutamine on Clinical Outcomes in Critically Ill Patients
Status:
Completed
Trial end date:
2018-09-10
Target enrollment:
Participant gender:
Summary
Glutamine supplementation has beneficial effects on morbidity and mortality in critically ill
patients, possibly in part through an attenuation of the proinflammatory cytokine response
and a Immune function. In this trial intensive care unit patients with enteral feeding will
receive either enteral glutamine or maltodextrin as placebo for 28 days.